721
Views
34
CrossRef citations to date
0
Altmetric
Review Article

GOLD: human exposure and update on toxic risks

Pages 596-614 | Received 05 Jun 2018, Accepted 16 Aug 2018, Published online: 17 Dec 2018

References

  • Abdelhalim MAK, Jarrar BM. 2012. Histological alterations in the liver of rats induced by different gold nanoparticle sizes, doses and exposure duration. J Nanobiotechnol. 10:5–9.
  • Abo-zeid MAM, Liehr T, Glei M, Gamal-eldeen AM, Zawrah M, Ali M. 2015. Detection of cyto- and genotoxicity of rod- shaped gold nanoparticles in human blood lymphocytes using Comet-FISH. Cytologia. 80:173–181.
  • Ahmed SV, Sajjan R. 2009. Chrysiasis: a gold “curse”! Br Med J Case Reports. 2009:bcr0720080417.
  • Ahnlide I, Björkner B, Bruze M, Möller H. 2000 . Exposure to metallic gold in patients with contact allergy to gold sodium thiosulfate. Contact Derm. 43:344–350.
  • Alani RM, Busam K. 2001. Acupuncture granulomas. J Am Acad Dermatol. 45:S225–S226.
  • Alkilany A, Murphy C. 2010. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res. 12:2313–2333.
  • Almarzouqi M, Scarsbrook D, Klinkhoff A. 2007. Gold therapy in women planning pregnancy: outcomes in one center. J Rheumatol. 34:1827–1831.
  • Alpers CN, Hunerlach MP, May JT, Hothem RL. 2005. Mercury contamination from historical gold mining in California. U.S. Geological Survey Scientific Investigations Report Version 1, Vol. 61.
  • Ansell BM, 1999. Prognosis in juvenile arthritis. Adv Exp Med Biol. 455:27–33.
  • Ansell BM, Crook A, Mallard JR, Bywaters EGL. 1963 . Evaluation of intra-articular colloidal gold AU198 in the treatment of presistent knee effusions. Ann Rheum Dis. 22:435–439.
  • Anon. 1892. The keeley gold cure for inebrity. Brit Med J. 2:85–86.
  • Antonovych TT. 1981. Gold nephropathy. Ann Clin Lab Sci. 11:386–391.
  • Apostoli P, De Palma G, Catalani S, Bortolotti F, Tagliaro F. 2009. Multielemental analysis of tissues from Cangrande della Scala. In the 14th century. J Anal Toxicol. 33:322–327.
  • Armstrong BK, McNulty JC, Levitt LJ, Williams KA, Hobbs MS. 1979. Mortality in gold and coal miners in Western Australia with special reference to lung cancer. Br J Ind Med. 36:199–205.
  • Aro T, Kanerva L, Häyrinen-Immonen R, Silvennoinen-Kassinen S, Konttinen YT, Jolanki R, Estlander T. 1993. Long-lasting allergic patch test reaction caused by gold. Contact Derm. 28:276–281.
  • Backman JT, Siegle I, Fritz P. 1998. Immunohistochemical localisation of metallothionein in synovial tissue of patients with chronic inflammatory and degenerative joint disease. Virchows Arch. 433:153–160.
  • Baek SY, Lee MG, Choi HY, Cho KS, Auh YH. 1992. Radiography, US, and CT of acupuncture needles in the abdominal organs. J Comput Assist Tomogr. 16:834–835.
  • Balkau F. 2000. Cyanide management in gold mining: an industrial code. Int Council Met Environ. 8:4.
  • Baptiste MS, Rothenberg R, Nasca PC, Janerich DT, Stutzman CD, Rimawi K, O’Brien W, Matuszek J. 1984. Health effects associated with exposure to radioactively contaminated gold rings. J Am Acad Dermatol. 10:1019–1023.
  • Barchanski A, Taylor U, Sajti CL, Gamrad L, Kues WA, Rath D, Barcikowski S. 2015. Bioconjugated gold nanoparticles penetrate into spermatozoa depending on plasma membrane status. J Biomed Nanotechnol. 11:1597–1607.
  • Bastús NG, Sánchez-Tilló E, Pujals S, Farrera C, Kogan MJ, Giralt E, Celada A, Lloberas J, Puntes V. 2009. Peptides conjugated to gold nanoparticles induce macrophage activation. Mol Immunol. 46:743–748.
  • Behrstock BB, Petrakis NL. 1974. Case reports. Permanent subcutaneous gold acupuncture needles. West J Med. 121:140–142.
  • Benedek TG. 2004 . The history of gold therapy for tuberculosis. J Hist Med Allied Sci. 59:50–89.
  • Benn HP, Schrier C, Bauer E, Seiler KU, Elhöft H, Löffler H. 1991. Biliary, renal and fecal elimination and distribution of gold after a single oral administration of auranofin, quantified by the instrumental neutron activation analysis method. Z Rheumatol. 50:32–38.
  • Benn H-P, von Gaudecker B, Czank M, Loeffler M. 1990. Crystalline and amorphous gold in chrysiasis. Arch Dermatol Res. 282:172–178.
  • Bennett PN, Humphries SJ, Osborne JP, Clarke AK, Taylor A. 1990. Use of sodium aurothiomalate during lactation. Br J Clin Pharmacol. 29:777–779.
  • Berners-Price SJ. 2011. Gold-based therapeutic agents. A new perspective. In: Alessio E, editor. Bioinorganic medicinal chemistry. 1st ed. GmbH, Weinheim, German: Wiley-VCH Verlag; p. 197–222.
  • Best PL, Sadler PJ. 1996. Gold drugs: mechanism of action and toxicity. Gold Bull. 29:87–93.
  • Blackwell TS, Gossage JR. 1995 . Gold pulmonary toxicity in a patient with a normal chest radiograph. South Med J. 88:644–646.
  • Blau SP. 1973. Metabolism of gold during lactation. Arthritis Rheum. 16:777–778.
  • Blocka K. 1983 . Auranofin versus injectable gold. Comparison of pharmacokinetic properties. Am J Med. 75:114–122.
  • Bonet M, Olive A, Maymo J, Cucurull J, Nogueroles A, Arnal C. 1990. Chrysiasis in rheumatoid arthritis. Clin Rheumatol. 9:254–255.
  • Bonnetblanc JM. 1996. Cutaneous reactions to gold salts. Presse Med. 25:1555–1558.
  • Botzvadze ES, Mosulishvili LM, Kuchava NE, Ghinturi EN. 1969. Studies of blood gold levels in patients with jaundice using neutron activation analysis. Phys Med Biol. 14:19–26.
  • Bouts BA. 1999 . Images in clinical medicine. Argyria. N Engl J Med. 340:1554
  • Brands HW. 2003. The age of gold: the California gold rush and the New American Dream. 14th ed. New York: Anchor Books; p. 592.
  • Brune D, Nordberg G, Wester PO. 1980. Distribution of 23 elements in the kidney, liver and lungs of workers from a smeltery and refinery in North Sweden exposed to a number of elements and of a control group. Sci Total Environ. 16:13–35.
  • Budden MG, Wilkinson DS. 1974. Skin and nail lesions from gold potassium cyanide. Contact Dermatitis. 4:172–173.
  • Burrows D, Adams RM. 1990. Metals. In: Adams RM, editor. Occupational skin disease. Philadelphia: W.B. Saunders; p. 367–369.
  • Butt TR, Sternberg EJ, Mirabelli CK, Crooke ST. 1986. Regulation of metallothionein gene expression in mammalian cells by gold compounds. Mol Pharmacol. 29:204–210.
  • Calamai P, Carotti S, Guerri A, Messori L, Mini E, Orioli O, Sperioni GP. 1998. Cytotoxic effects of gold (III) complexes on established human tumour cell tines sensitive and resistant to cisplatin. Anticancer Drug Res. 13:67–80.
  • Callery EM. 1989. Cancer caused by radioactive gold rings. Can Med Ass J. 141:507.
  • Cardoso E, Londero E, Ferreira GK, Rezin GT, Zanoni ET, de Souza Notoya F, Leffa DD, Damiani AP, Daumann F, Rohr P, et al. 2014. Gold nanoparticles induce DNA damage in the blood and liver of rats. J Nanopart Res. 16:2727–28pp.
  • Centers for Disease Control and Prevention. 2017. Gold miners (silica exposure), Worker Health Study Summaries. CDC, Atlanta, Ga: NIOSH Publications and Products.
  • Chanda N, Kan P, Watkinson LD, Shukla R, Zambre A, Carmack TL, Engelbrecht H, Lever JR, Katti K, Fent GM, et al. 2010. Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumour-bearing mice. Nanomed: Nanotechnol, Biol Med. 6:201–209.
  • Chattopadhyay A, Sarkar M, Biswas NM. 2006. Effect of gold on stimulation of reproductive function in immature female albino rats. Indian J Exp Biol. 44:971–975.
  • Chen YH, Tsai CY, Huang PY. 2007. Methotrexate conjugated to gold nanoparticles inhibits tumour growth in a synergistic lung tumour model. Mol Pharm. 4:713–722.
  • Cheriathundam E, Alvares AP, 1996. Species differences in the renal toxicity of the antiarthritic drug, gold sodium thiomalate. J Biochem Toxicol. 11:175–181.
  • Chithrani DB, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, Hill RP, Jaffray DA. 2010. Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res. 173:719–728.
  • Christian GD, 1965. Polarographic determination of traces of gold in blood and serum. Clin Chem. 11:459–464.
  • Clark P, Tugwell P, Bennett K, Bombardier C, 1989 . Meta-analysis of injectable gold in rheumatoid arthritis. J Rheumatol. 16:442–447.
  • Coghlan A. 1996. Cleaner gold improves miners’ prospects. New Scientist. 11.
  • Cohen D, Orzel J, Taylor A. 1981. Infants of mothers receiving gold therapy. Arthritis Rheum. 24:104–105.
  • Cohen PR, Ross EV, 2015. Q-switched alexandrite laser-induced chrysiasis. J Clin Aesthet Dermatol. 8:48–53.
  • Cullen RT, Tran CL, Buchanan D, Davis JM, Searl A, Jones AD, Donaldson K. 2000. Inhalation of poorly soluble particles. I. Differences in inflammatory response and clearance during exposure. Inhal Toxicol. 12:1089–1111.
  • Danscher G, Hansen HJ, Møller-Madsen B. 1984. Energy dispersive X-ray analysis of tissue gold after silver amplification by physical development. Histochemistry. 81:283–285.
  • Danscher G. 2002. In vivo liberation of gold ions from gold implants. Autometallographic tracing of gold in cells adjacent to metallic gold. Histochem Cell Biol. 117:447–452.
  • Davis P. 1988. Gold therapy in the treatment of rheumatoid arthritis. Can Fam Physician. 34:445–452.
  • de Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJM, Geertsma RE. 2008. Particle size-dependent distribution of gold nanoparticles after intravenous administration. Biomater. 29:1912–1919.
  • De Jong WH, Hagens WI, Krystek P, Burger P, Sips AJ, Geertsma RE. 2008. Particle size-dependent distribution of gold nanoparticles after intravenous administration. Biomater. 29:1912–1919.
  • De Mey J. 1983. Colloidal gold probes in immunocytochemistry. In Polak JM, and Van Noorden S, editors. Immunocytochemistry, practical applications in pathology and biology. 1st ed. Amsterdam: Eslevier. Chapter 6; p. 82–112.
  • Demann ET, Stein PS, Haubenreich JE, 2005. Gold as an implant in medicine and dentistry. J Long Term Eff Med Implants. 15:687–698.
  • Dillard CT, Hu ML, Tappel AL. 1987. Effect of aurothioglucose on glutathione and glutathione-metabolising and related enzymes in rat liver and kidney. Chem Biol Interact. 64:103–114.
  • Donaldson JA. 1980. The use of gold in dentistry: an historical overview. Gold Bull. 13:117–124.
  • Doudi M, Setorki M. 2014. The acute liver injury caused by gold nanoparticles. Nanomed J. 1:248–257.
  • Doyi I, Oppon OC, Glover ET, Gbeddy G, Kokroko W, 2013. Assessment of occupational radiation exposure in underground artisanal mines in Tongo, Upper East Region of Ghana. J Environ Radiol. 126:77–82.
  • Drasch G, Muss C, Roider G, 2000. Gold and palladium burden from dental restoration materials. J Trace Elem Med Biol. 14:71–75.
  • Eisler R, Wiemeyer SN. 2004. Cyanide hazards to plants and animals from gold mining and related water issues. Rev Environ Contam Toxicol. 183:21–54.
  • Eisler R. 2003 . Health risks of gold miners: a synoptic review. Environ Geochem Health. 25:325–345.
  • Eisler R. 2004. Mercury hazards from gold mining to humans, plants and animals. Rev Environ Contam Toxicol. 181:139–198.
  • Elsome AM, Hamilton-Miller JM, Brumfitt W, Noble WC. 1996. Antimicrobial activities in vitro and in vivo of transition complexes containing gold(I) and osmium,(VI). J Antimicrob Chemoth. 37:911–918.
  • European Commission. 2016. Scientific Opinion on the re-evaluation of gold (E175) as a food additive. Eur Food Safety Authority J. 14:4362–4405.
  • Faraday M. 1857. Experimental relations of gold (and other metals) to light. Phil Trans R Soc. London. 147:145–181.
  • Fernández de Castro I, Sanz-Sánchez L, Risco C. 2014. Metallothioneins for correlative light and electron microscopy. Methods Cell Biol. 124:55–70.
  • Fisher AA, Shapiro A. 1959. Allergic eczematous contact dermatitis due to metallic nickel. J Am Med. 80:745–761.
  • Fisher AA. 1968. Contact dermatitis from gold wedding ring. J Am Med Ass. 205:318.
  • Fisher AA. 1978. Contact dermatitis. 3rd ed. Philadelphia (PA): Lea and Febiger.
  • Fleischner GM, Morecki R, Hanaichi H, Hayashi H, Quintana N, Sternlieb I. 1991. Light and electron microscopical study of a case of gold salt-induced hepatotoxicity. Hepatology. 14:422–425.
  • Fowler JC, 1987. Selection of patch test materials for gold allergy. Contact Dermatitis. 17:23–25.
  • Franklin C. 1965. Golden gun blasts cancer cells. New Sci. 23.
  • Freeman SJ, Lloyd JB. 1966. Evidence that suramin and aurothiomalate are teratogenic in rat by disturbing yolk sac-mediated embryonic protein nutrition. Chem Biol Interact. 58:149–160.
  • Freyberg RH, Block WD, Levey S. 1941. Metabolism, toxicity and manner of action of gold componds used in the treatment of arthritis. I. Human plasma and synovial fluid concentration and urinary excretion of gold during and following treatment with gold sodium thiomalate, gold sodium thiosulphate, and colloidal gold sulphide. J Clin Invest. 20:401–412.
  • Fricker SP. 1996. P. Medical uses of gold compounds: past present and future. Gold Bull. 29:53–60.
  • Galbraith PJ, Richardson ML. 2006. Permanently retained acupuncture needles: radiographic findings and case report. Radiol Cas Rep. 1:120–122.
  • Gangolli SD, Grasso P, Golberg L. 1967. Physical factors determining early local tissue reactions produced by food colourings and other compounds injected subcutaneously. Food Cosmet Toxicol. 5:601–621.
  • Ganley CJ, Paget SA, Reidenberg MM. 1989. Increased renal tubular cell excretion by patients receiving chronic therapy with gold and with non-steroidal anti-inflammatory drugs. Clin Pharmacol Ther. 46:51–55.
  • Gasull MV. 2012. Polysaccharide-gold nanoparticles as anticancer drug carriers, Thesis. Faculty of Engineering of the University of Porto, Porto, Portugal.
  • Gerber A, Bundschuh M, Klingelhofer D, Groneberg DA. 2013. Gold nanoparticles: recent aspects for human toxicology. J Occup Med Toxicol. 8:32–42.
  • Ghadially FN, DeCoteau WE, Huang S, Thomas I, 1978. Ultrastructure of the skin of patients treated with sodium aurothiomalate. J Pathol. 124:77–83.
  • Girdwood RH. 1974. Death after taking medicaments. Br Med J. 1:501–504.
  • Gjuric M, Schagerl S, 1998. Gold prostheses for ossiculoplasty. Am J Otol. 19:273–276.
  • Goodman P. 2002. Current and future uses of gold in electronics. Gold Bull. 35:21–26.
  • Gottleib NL, Smith PM, Penneys NS, Smith EM. 1974. Gold concentrations in hair, nail and skin. Arthrit Rheum. 17:56–62.
  • Gottleib NL. 1979. Gold excretion and retention during auranofin treatment: a preliminary report. J Rheumatol. 5:61–67.
  • Gottlieb NL, Major JC, 1978. Ocular chrysiasis correlated with gold concentrations in the crystalline lens during chrysotherapy. Arthritis Rheum. 21:704–708.
  • Grahame R, Billings R, Laurence M, Marks V, Wood PJ, 1974. Tissue gold levels after chrysotherapy. Ann Rheum Dis. 33:536–539.
  • Grasso P, Golberg L. 1966 . Subcutaneous sarcoma as an index of carcinogenic potency. Food Cosmet Toxicol. 4:297–320.
  • Green F. 2000. Pulmonary responses to inhaled poorly soluble substances in the human. Inhalat. Toxicol. 12:59–95.
  • Gregus Z, Klaassen CD. 1986. Disposition of metals in rats: comparative study of fecal, urinary and biliary secretion and tissue distribution of eighteen metals. Toxicol Appl Phrmacol. 85:24–38.
  • Griffin AJ. 1979. Cholestatic hepatitis induced by gold. Rheumatol Rehabil. 18:174–176.
  • Gromnicova R, Davies HA, Sreekanthreddy P, Romero IA, Lund T, Roitt IM, Phillips JB, Male DK. 2013. Glucose-coated gold nanoparticle transfer across human brain endothelium and enter astrocytes in vitro. PLoS One. 8:e81043–e81014.
  • Grubb BR, Bentley PJ, 1988. Accumulation and toxicity of gold in the rabbit lens in vitro. Exp Eye Res. 46:637–645.
  • Grubb BR, Matthews O, Bentley PJ, 1986. Ocular chrysiasis: accumulation of gold in the rabbit eye. Curr Eye Res. 5:891–8893.
  • Hauck TS, Ghazani AA, Chan WC, 2008. Assessing the focal effect of surface chemistry on gold nanorod uptake, toxicity and gene expression in mammalian cells. Small. 4:153–159.
  • Haume K, Rosa S, Grellet S, Śmiałek MA, Butterworth KT, Solov’yov AV, Prise KM, Golding J, Mason NJ. 2016. Gold nanoparticles for cancer radiotherapy: a review. Cancer Nano. 7:1–20.
  • Heath MJ, 1988 . Measurement of ‘free’ gold in patients receiving disodium aurothiomalate and the association of high free to total gold levels with toxicity. Ann Rheum Dis. 47:18–21.
  • Heath MJ, Gillett GT, Swannell AJ, Williams CR, Palmer T, 1987 . Patterns of gold levels in urine, serum, and saliva in patients with rheumatoid arthritis undergoing chrysotherapy. Ann Rheum Dis. 46:827–829.
  • Henderson B, Raynor GV. 1962. The effective valencies of transition metals in solid solution in gold and silver alloys. Proc Roy Soc London, Ser A. Mathem Phys Sci. 267:313–328.
  • Higby GJ. 1982. Gold in medicine: a review of its use in the west before 1900. Gold Bull. 15:130–140.
  • Hillyer JF, Albrecht RM. 2001. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharm Sci. 90:1927–1136.
  • Hnizdo E, Sluis-Cremer GK. 1991. Silica exposure and lung cancer: a mortality study in South African gold miners. Int Congress Occup Health. 48:53.
  • Huang Y, Yu F, Park Y-S, Wang J, Shin M-C, Chung HS, Yang VC. 2010. C. Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomater. 31:9086–9091.
  • Hughes MO. 2010. Incorporating gold into ocular prosthetics. J Ophthalm Prosthetics. 15:37–43.
  • Hunt LB. 1976. The true story of Purple of Cassius; the birth of gold-based glass and enamel colours. Gold Bull. 9:134–139.
  • Husserl FE, Shuler SE. 1979 . Gold nephropathy in juvenile rheumatoid arthritis. Am J Dis Child. 133:50–52.
  • James WD, Hirsch LR, West JL, O’Neal PD, Payne JD, 2007. Application of INAA to build up and clearance of gold nanoshells in clinical studies in mice. J Radioanal Nucl Chem. 271:455–459.
  • Jauniaux E, Moscoso JG. 1992. Morphology and significance of the human yolk sac. In: ER Barnes, editor. The First Twelve weeks of gestation. Berlin: Springer; p. 192–213.
  • Jeffery D, Biggs DF, Percy JS, Russell AS, 1975. Quantitation of gold in skin in chrysiasis. J Rheumatol. 2:28–35.
  • Jellum E, Munthe E. 1980. Biochemical and physical effects of penicillamine and other thiols used in the treatement of rheumatoid arthritis. In: Cavallini D, Gaull GE, and Zappia V, editors Natural Sulphur Compounds. Boston, MA: Springer; p. 375–380.
  • Jia YP, Ma BY, Wei XW, Qian ZY. 2017. The in vitro and in vivo toxicity of gold nanoparticles. Chinese Chem Lett. 28:691–702.
  • Jo MR, Bae SH, Go MR, Kim HJ, Hwang YG, Choi SJ. 2015. Toxicity and biokinetics of colloidal gold nanoparticles. Nanomaterials (Basel). 5:835–850.
  • Jonas L, Fulda G, Nizze H, 2007. Detection of gold particles in the neck skin after a lightening stroke with evaporation of an ornamental chain. Ultrastruct Pathol. 26:153–159.
  • Jones G, Brooks PM. 1996. Injectable gold compounds: an overview. Br J Rheumatol. 35:1154–1158.
  • Jones RA, Ahmed MU, Chan BW, 1971. Gold excretion in rheumatoid arthritis. Br Med J. 1:610
  • Kabir H, Bilgi C, 1993. Ontario gold miners with lung cancer. Occupational exposure assessment in establishing work-relatedness. J Occup Med. 35:1203–1207.
  • Kanerva L. 1989. Electron microscopy of epidermal and dermal Langerhans cells in long-lasting allergy patch tests. Arch Dermatol. 281:321–326.
  • Katz WA, Blodgett RC, Pietrusco RG. 1984. Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med. 10:176–179.
  • Keen CE, Brady K, Kirkham N, Levison DA, 1993. Gold in the dermis following chrysotherapy: histopathology and microanalysis. Histopathology. 23:355–360.
  • Kesler SE, Chryssoulis SL, Simon G. 2002. Gold in porphyry copper deposits:its abundance and fate. Ore Geol Rev. 21:103–124.
  • Kim JH, Kim JH, Kim KW, Kim MH, Suk Y. 2009. Intravenously administered gold nanoparticles pass through the blood-brain barrier depending on the particle size and induce no retinal toxicity. Nanotechnology. 20:505101.
  • Kim YJ, Kim DH, Seo YJ, 2010. Gold is skin deep: Multiple facial foreign body granuloma caused by injection of gold acupuncture needle. J Am Acad Dermatol. 62:AB33.
  • Kirkemo H, Newman WL, Ashley RP. 1997. Gold, U.S. Geological Survey. Denver, (CO): Information Services; p. 1–5.
  • Klaassen CD, Liu J, Choudhuri S. 1999. Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol. 39:267–294.
  • Kligman AM. 1978 . Cutaneous toxicology: an overview from the underside. Curr Probl Dermatol. 7:1–25.
  • Krusius F-E, Markkanen A, Peltola P, 1970. Plasma levels and urinary excretion of gold during routine treatment of rheumatoid arthritis. Ann Rheum Dis. 29:232–235.
  • Kubba A, Kubba R, Batrani M, Pal T, 2013. Argyria, an unrecognised cause of cutaneous pigmentation in Indian patients. A case series and review of the literature. Indian J Dermatol Venereol Leprol. 79:805–811.
  • Kusiak RA, Springer J, Ritchie AC, Muller J. 1991. Carcinoma of the lung in Ontario gold miners: possible aetiological factors. Br J Ind Med. 48:808–817.
  • Laeijendecker R, Van Joost T. 1994. Oral manifestations of gold allergy. J Am Acad Dermatol. 30:205–209.
  • Langley RC. 1971. Gold coatings for temperature control in space exploration. Gold Bull. 4:62–66.
  • Lansdown ABG, 2018. Titanium dioxide: a dilemma for pathologists and regulators. Bull Roy Coll Pathol. 181:20.
  • Lansdown ABG, Sampson B, Rowe AM. 2001. Experimental observations in the rat on the influence of cadmium on skin wound repair. Int J Exp Pathol. 82:35–41.
  • Lansdown ABG. 2007. Critical observations on the neurotoxicity of silver. Crit Rev Toxicol. 37:237–350.
  • Lansdown ABG. 2011. Metal ions affecting the skin and eyes. In: Siegel A, Siegel H, Siegel RKO, editors. Metal Ions in Life Sciences. Vol. 8, Cambridge: Royal Society of Chemistry; p. 187–246.
  • Lansdown ABG. 2014. Precious metals, silver, gold and platinum-related metals, In The Carcinogenicity of Metals: human risk through occupational and environmental exposure, Cambridge: Royal Society of Chemistry. Chapter 13; p. 278–300.
  • Lansdown ABG. 2012. Silver and gold. In Bingham E and Cohrssen B, editiors. Patty’s Toxicology. 6th ed. Vol. 1, Hoboken (NJ): Wiley; p. 75–112.
  • Lansdown ABG. 2010. Silver in Healthcare; its antimicrobial efficacy and safety in use. Cambridge: Royal Society of Chemistry Publishing.
  • Larsen WG, Adams RM, Maibach HI. 1992. Color Text of Contact Dermatitis. Philadelphia: W.B. Saunders; p. 210–211.
  • Lawrence JS. 1976. Comparative toxicology of gold preparations in treatment of rheumatoid arthritis. Ann Rheum Dis. 35:171–173.
  • Leonard PA, Moatamed F, Ward JR, Piepkorn MW, Adams EJ, Knibbe WP, 1986. Chrysiasis: the role of sun exposure in dermal hyperpigmentation secondary to gold therapy. J Rheumatol. 13:58–64.
  • Lichtenstein MR, 1935. The patch test for gold hypersensitivity. J Allergy. 6:460–463.
  • Lightfoot NE, Pacey MA, Darling S, 2010. Gold, nickel and copper mining and processing. Chronic Dis Can. 29:101–124.
  • López JD, del Castillo JM, López CD, Sánchez JG, 2003. Confocal microscopy in ocular chrysiasis. Cornea. 22:573–575.
  • Lorey F. 2017. A Guide to the Gold Rush Country of California. Mt. Pleasant, (SC): Arcadia Pub. Co, Fonthill, Media LLC.
  • Lowthian PJ, Cleland L, Vernon-Roberts B. 1984. Hepatotoxicity with aurothioglucose. Arthritis Rheumatol. 27:230–232.
  • Madzivire G, Maleka P, Lindsay R, Petrik IF, 2014. Radioactivity of mine water from a gold mine in South Africa. Transact Ecol Environm. 178:147.
  • Mason RW, 1983. Time course of gold-induced accumulation of copper and zinc and the effects of dimercaptosuccinate and cadmium on gold metabolism in rat kidney. Chemico-Biological Interactions. 43:199–208.
  • McCormick SA, DiBartolomeo AG, Raju VK, Schwab IR. 1985. Ocular chrysiasis. Ophthalmology. 92:1432–1435.
  • Merle LJ, Reidenberg MM, Camacho MT, Jones BR, Drayer DE. 1980. Renal injury in patients with rheumatoid arthritis treated with gold. Clin Pharmacol Ther. 28:216–222.
  • Mhashal AR, Roy S. 2014. Effect of gold nanoparticle on structure and fluidity of lipid membrane. PLoS One. 9:e114152.
  • Miller RA, Aldrich JE. 1990. Radioactive gold ring dermatitis. J Am Acad Dermatol. 23:360–362.
  • Mohr F, Sanzb S, Vergara E, Cerrada E, Laguna M. 2006. Water-soluble and water-stable gold (I), gold (III) and gold (III) phosphine complexes:the early years. Gold Bull. 39:212–215.
  • Möller H, 2002. Dental gold alloys and contact allergy. Contact Derm. 47:63–66.
  • Möller H, Schütz A, Björkner B, Bruze M. 2004 . Percutaneous absorption of gold sodium thiosulfate used for patch testing. Contact Derm. 51:63–66.
  • Møller-Madsen B, Danscher G. 1983. Transplacental transport of gold in rats exposed to sodium aurothiomalate. Exp Mol Pathol. 39:327–331.
  • Monia BP, Butt TR, Mirabelli CK, Ecker DJ, Sternberg E, Crooke ST. 1987 . Induction of metallothionein is correlated with resistance to auranofin, a gold compound, in Chinese hamster ovary cells. Mol Pharmacol. 31:21–26.
  • Moretti E, Terzuoli G, Renieri T, Iacoponi F, Castellini C, Giordano C, Collodel N. 2012. In vitro effect of gold and silver nanoparticles on human spermatozoa. Andrologica. 45:392–396.
  • Murawala P, Tirmale A, Shiras A, Prasad BLV. 2014. In situ synthestized BSA-capped gold nanoparticles: effective carrier of anticancer drug methotrexate to MCF-7 breast cancer cells. Mater Sci Eng C Mater Biol Appl. 34:158–167.
  • Myllynen PK, Loughran MJ, Howard CV, Sormunen R, Walsh AA, Vähäkangas KH. 2008. Kinetics of gold nanoparticles in the human placenta. Reprod Toxicol. 26:130–137.
  • Nagi AH, Alexander F, Barabas AZ. 1971 . Gold nephropathy in rats-light and electron microscopic studies. Exp Mol Pathol. 15:354–362.
  • Needs CJ, Brooks PM. 1985. Antirheumatic medication in pregnancy. Br J Rheumatol. 24:282–290.
  • Nelson G, 2013. Occupational respiratory diseases in the South African mining industry. Glob Health Action. 6:19520.
  • Newton P, Swinburn WR, Swinson DR. 1983. Proteinuria with gold therapy: when should gold be permanently stopped? Br J Rheumatol. 22:11–17.
  • Oberdörster G, 1988. Lung clearance of inhaled insoluble and soluble particles. J Aerosol Med. 1:289–330.
  • Oberdörster G, Elder A, Rinderknecht A. 2009. Nanoparticles and the brain: cause for concern? J Nanosci Nanotechnol. 9:4996–4500.
  • Oliver C. 1999. Preparation of colloidal gold. Methods Mol Biol. 115:327–330.
  • Ostensen M, Skavdal K, Myklebust G, Tomassen Y, Aarbakke J, 1986. Excretion of gold into human breast milk. Eur J Clin Pharmacol. 31:251–252.
  • Oxman AD, Muir DC, Shannon HS, Stock SR, Hnizdo E, Lange HJ. 1993. Occupational dust exposure and chronic pulmonary disease. A systemic overview of the evidence. Am Rev Respir Dis. 148:38–48.
  • Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L. 2004. Colloidal gold: novel nanoparticle vector for tumour directed drug delivery. Drug Deliv. 11:169–183.
  • Paino IMM, Marangoni VS, de Oliveira R. d C S, Antunes LMG, Zucolotto V. 2012. Cyto- and genotoxicity of gold nanoparticles in human hepatocellular carcinoma and peripheral blood mononuclear cells. Toxicol Lett. 215:119–125.
  • Paladini I, Menchini U, Mencucci R, 2010. Corneal chrysiasis: in vivo confocal microscopy analysis. Eur J Ophthalmol. 20:776–779.
  • Pan Y, Neuss S, Leifert A, Fischler A, Wen F, Simon U, Schmid G, Brandau W, Jahnen-Dechet W, 2007 . Size-dependent cytotoxicity of gold nanoparticles. Small. 3:1941–1949.
  • Payne BJ, Saunders LZ. 1978. Heavy metal nephropathy in rodents. Vet Pathol. 15:51–87.
  • Payne BJ. 1978. Sarcoma at the injection site of gold sodium thiomalate. Vet Pathol. 15:39–50.
  • Pedersen SM, 1981. The binding of gold to human albumin in vitro, intrinsic association constants at physiological conditions. Biochem Pharmacol. 30:3249–3252.
  • Pelachyk JM, Bergfeld WF, McMahon JT. 1984. Chrysiasis following gold therapy for rheumatoid arthritis: ultrastructural analysis with X-ray energy spectroscopy. J Cutan Pathol. 11:491–494.
  • Penneys NS, Ackerman AB, Gottleib NL. 1974. Gold dermatitis. A clinical and histopathological study. Arch Dermatol. 109:372–376.
  • Powell AC, Pacioti GF, Libutti SK. 2010. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol Biol. 624:375–384.
  • Prouse PJ, Kanski JJ, Gumpel JM, 1981. Corneal chrysiasis and clinical improvement with chrysotherapy in rheumatoid arthritis. Ann Rheum Dis. 40:564–566.
  • Raj A, Williams GP, Hawksworth NR, 2012. Ulcerative keratitis following particulate elemental gold deposition. J Ocul Pharmacol. 28:323–325.
  • Ramanakumar AV, Parent M-É, Latreille B, Siemiatycki J. 2008. Risk of lung cancer following exposure to carbon black, titanium dioxide and talc. Results from two case-control studies in Montreal. Int J Cancer. 122:183–189.
  • Rapson WS. 1995. Skin contact with gold and gold alloys. Contact Dermatitis. 13:56–65.
  • Research Subcommittee of the Empire Rheumatism Council. 1960. Gold therapy in rheumatoid arthritis: report of a multicentre controlled trial. Ann Rheum Dis. 19:95–119.
  • Roberts AVS, Williams KE, Lloyd JB. 1977. The pinocytosis of 125I-labelled poly(vinylpyrrolidone), [14C] sucrose and colloidal [198Au] gold by the rat yolk sac cultured in vitro. Biochem J. 168:239–244.
  • Roberts WH, Wolter JR, 1956. Ocular chrysiasis. AMA Arch Ophthalmol. 56:48–52.
  • Rocker I, Henderson WJ. 1976. Transfer of gold from mother to fetus. Lancet. 308:1246.
  • Roest MAB, Ratnavel R, 2001. Yellow nails associated with gold therapy for rheumatoid arthritis. Br J Dermatol. 145:855–856.
  • Rooney TW, Lorber A, Veng-Pedersen P, Furst D. 1988. Gold pharmacokinetics in breast milk and serum of a lactating woman. J Rheumatol. 14:1120–1122.
  • Rothwell RS, Schloss EH. 1980. Granuloma annulare and gold therapy. Arch Dermatol. 116:863.
  • Rye B, Krusinski PA. 1993. Hepatonecrosis resulting from parenteral gold therapy in pemphigus vulgaris. J Am Acad Dermatol. 28:99–101.
  • Sakulsak N, 2012. Metallothionein: an overview on its metal homeostatic regulation in mammals. Int J Morphol. 30:1007–1012.
  • Santos-Bueso E, Ahmed-Wasfy M, Sáenz-Francés F, Gil-de-Bernabé J, Martinez-de-la- Casa JM, Benitez-del Castillo JM, Garcia-Feijoo J, 2013. Corneal chrysiasis. Gold salt deposits in the cornea in a patient with rheumatoid arthritis. An analysis with confocal microscopy. Arch Soc Epan. 88:237–239.
  • Schaeublin NM, Braydich-Stolle LK, Schrand AM, Miller JM, Hutchison J, Schlager JJ, Hussain SM. 2011. Surface charge of gold nanoparticles mediates mechanism of toxicity. Nanoscale. 3:410–420.
  • Schering SOLGANOL. 2010. ®Aurothioglucose antirheumatic agent. Pharm Info Monogr. 1–8.
  • Schleh C, Semmler-Behnke M, Lipka J, Wenk A, Hirn S, Schäffler M, Schmid G, Simon U, Kreyling WG. 2012. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicol. 6:36–46.
  • Schmitz G, Minkel DT, Gingrich D, Shaw CF, 1980 . The binding of Gold(I) to metallothionein. J Inorg Biochem. 12:293–306.
  • Sela H, Cohen H, Elia P, Zach R, Karpas Z, Zeiri Y. 2015 . Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB). J Nanobiotechnol. 13:71
  • Setty BNY, Betal SG, 2008. Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine positive erythrocytes. Blood. 111:905–914.
  • Shacklette HT, Lakin HW, Hubert AE, Curtin GC. 1970. Absorption of gold by plants. Geol Surv Bull. 1314-B:1–23.
  • Sharma RP, Smillie J, Laverly R. 1964. Triethylphosphine gold: cellular uptake and deposition after single and repeated oral doses in rats. J Pharm Pharmacol. 36:441–445.
  • Sharma RP, Smillie J, Palmer DG, 1985. Gold concentrations and toxicity during oral gold treatment with auranofin. Pharmacology. 30:115–120.
  • Shelley WB, Epstein E, 1963 . Contact-sensitivity to gold as a chronic papular eruption. Arch Dermatol. 87:388–391.
  • Shrivastava R, Kushwaha P, Bhutia YC, Flora SJS. 2016. Oxidative stress following exposure to silver and gold nanoparticles in mice. Toxicol Ind Health. 32:1391–1404.
  • Shuh A, Fritsch A, Ginepro JQ, Heim M, Shore A, Thoennessen M. 2012. Discovery of the Gold Isotopes. In: John E, editiors. Elements 113, 115, 117 and 118. Cambridge: Royal Society of Chemistry.
  • Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M, 2005. Biocompatibility of gold nanoparticles and their endocytic fate inside the cellular compartment: a microscopic overview. Langmuir. 21:10644–10654.
  • Simonato L, Moulin JJ, Javelaud B, Ferro G, Wild P, Winkelmann R, Saracci R. 1994 . A retrospective mortality study of workers exposed to arsenic in a gold mine and refinery in France. Am J Ind Med. 25:625–633.
  • Singh AD, Puri P, Amos RS. 2004. Deposition of gold in ocular structures, although known, is rare. A case of ocular chrysiasis in a patient of rheumatoid arthritis on gold treatment is presented. Eye. 18:443–444.
  • Sisam DA, Sheehan JP. 1990. Chronic neutropenia following gold therapy. J Am Osteopath Assoc. 90:83–86.
  • Skornik WA, Brain JD, 1993. Relative toxicity of inhaled metal sulphate salts fo pulmonary macrophages. Am Rev Respir Dis. 128:297–303.
  • Small BW, 2009. The use of direct gold in restorative dentistry. Gen Dent. 57:108–111.
  • Smith JR, Bailey MR, Therington G, Shutt AL, Youngman MJ, 2008 . Effect of particle size on slow particle clearance from the bronchial tree. Exp Lung Res. 34:287–312.
  • Smith RW, Leppard B, Barnett NL, Millward-Sadler GH, McCrae F, Cawley MI, 1995. Chrysiasis revisited: a clinical and pathological study. Br J Dermatol. 133:671–678.
  • Sollimann T. 1942. Manual of Pharmacology. Philadelphia: Saunders.
  • Sonavane G, Tomoda K, Sano A, Ohshima H, Terada H, Makino K. 2008. In vitro permeation of gold nanoparticles through rat skin and rat intestine: effect of particle size. Colloids Surf B Biointerfaces. 65:1–10.
  • Speelman WJ, Lindsay R, Newman RT, de Meijer RJ. 2004. Radon generation and transport in and around a gold mine tailings dam in South Africa. Instr Methods Phys Res B. 213:775–778.
  • Spiegel SJ, Agrawal S, Mikha D. 2018. Phasing out mercury? Ecological economics and Indonesia’s small scale gold mining sector. Ecol Econo. 144:1–14.
  • Sung JH, Ji JH, Park JD, Song MY, Song KS, Ryu HR, Yoon JU, Jeon KS, Jeong J, Han BS, et al. 2011. Subchronic inhalation toxicity of gold nanoparticles. Part Fibre Toxicol. 8:16–39.
  • Sutton BM. 1983. Overview and current status of gold-containing antiarthritic drugs, In: Dabrowick JC, editiors. Metals in Medicine, ACS Symposium, Ch. 18. Washington (DC): ACS Publications; p. 355–369.
  • Suzuki H, Baba S, Uchigasaki S, Murase M, 1993. Localised argyria with chrysiasis caused by implanted acupuncture needles. J Am Acad Derm. 29:833–837.
  • Swanson JN. 1949 . Repeated colloidal gold tests in rheumatoid arthritis. Ann Rheum Dis. 8:232–237.
  • Szabo KT, Guerriero FJ, Kang YJ. 1978. The effects of gold-containing compounds on pregnant rats and their foetuses. Vet Pathol. 15:89–96.
  • Takenaka S, Karg E, Kreyling WG, Lentner B, Möller W, Behnke-Semmler M, Jennen L, Walch A, Michalke B, Schramel P, 2006 . Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal Toxicol. 18:733–740.
  • Takenaka S, Karg E, Kreyling WG, Lentner B, Möller W, Behnke-Semmler M, Jennen L, Walch A, Michalke B, Schramel P, et al. 2006. Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal Toxicol. 18:733–740.
  • Taylor U, Barchanski A, Petersen S, Rath D. 2013. Gold nanoparticles interfere with sperm functionality by membrane absorption without penetration. Nanotoxicology. 8:118–127.
  • Taylor U, Garrels W, Petersen S, Barcikowski S, Klein S, Kues A, Lucas-Hahn A, Niemnn H, Rath D. 2009. Development of murine embryos after injection of uncoated gold and silver nanoparticles. Reprod Fertil Dev. 22:240–241.
  • Taylor U, Tiedemann D, Rehbock C, Kues WA, Barcikowski S, Rath D. 2015. Influence of gold, silver and gold-silver alloy nanoparticles on germ cell function and embryo development. Beilstein J Nanotechnol. 6:651–664.
  • te Boekhorst PAW, Barrera P, Laan RFJM, van de Putte LBA. 1999. Hepatotoxicity of parenteral gold therapy in rheumatoid arthritis: a case report and review of the literature. Clin Exp Rheumatol. 17:359–362.
  • Terentyuk G, Akchurin G, Maksimova I. 2009. Tracking gold particles in the body. J Biophysics. 2:292–333302.
  • Tiekink ERT. 2008 . Anti-cancer potential of gold complexes. Inflammopharmacology. 16:138–142.
  • Tierney DW, 1988. Ocular chrysiasis. J Am Optom Assoc. 59:960–962.
  • Tsyganova NA, Khairullin RM, Terentyuk GS, Khlebtsov BN, Bogatyrev VA, Dykman LA, Erykov SN, Khlebtsov NG. 2014. Penetration of pegylated gold nanoparticles through rat placental barrier. Bull Exp Biol Med. 157:383–385.
  • U.S. Geological Survey. 2018. Department of the Interior, Washington (DC). Denver (CO): US Geological Survey, Information Services.
  • U.S.A. Gold. 2010. An overview of gold – weights and measures: physical and chemical properties. Denver (CO): U.S.A. Gold, Reference Library.
  • Uboldi C, Bonacchi D, Lorenzi G, Hermanns MI, Pohl C, Baldi G, Unger RE, Kirkpatrick CJ, 2009. Gold nanoparticles induce cytotoxicity in the alveolar type-II cell lines A549 and NCIH441. Part Fibre Toxicol. 6:18–29.
  • Wang Y, He QY, Che CM, Chiu JF. 2006 . Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug. Proteomics. 6:131–142.
  • Wang Y, Wan J, Miron RJ, Zhao Y, Zhang Y. 2016. Antibacterial properties and mechanisms of gold-silver nanocages. Nanoscale. 8:11143–11152.
  • Weisman MH, Hardison WG, Walz DT, 1980. Studies of the intestinal metabolism of oral gold. J Rheumatol. 7:633–638.
  • Wicks IP, Wong D, McCullagh RB, Fleming A, 1988. Contact allergy to gold after systemic administration of gold for rheumatoid arthritis. Ann Rheum Dis. 47:421–422.
  • Wiles FJ, Johnston JR, Le Roux AF, Churchill AR. 1982. Acute exposure to gold mine dust-a bronchial challenge test? Ann Occup Hyg. 26:663–675.
  • Williame LME, Joos R, Proot F, Immesoete C. 1987 . Gold-induced aplastic anemia. Clin Rheumatol. 6:600–605.
  • Wittsiepe J, Schrey P, Wilhelm M, Begerow J, Dunemann L, 2003. Dietary intake of platinum and gold by children from Germany using duplicate portion sampling. J Trace Elem Med Biol. 17:117–122.
  • Wiwanitkit V, Sereemaspun A, ansd Rojanathanes R. 2009. Effect of gold nanoparticles on spermatozoa: the first world report. Fertil Steril. 91:e7–e8.
  • World Gold Council. 2013. The Gold Mining Industry: Reputation and Issues. London: World Gold Council.
  • Wright V. 1984. Oral gold for rheumatoid arthritis. Br Med J. 289:858–859.
  • Yamanishi Y, Takeda M, Honjo N, Aoi K, Ishibe Y, Yamana S. 1992. Gold-induced severe cholestatic jaundice in rheumatoid arthritis patient and effect of repeated steroid pulse therapy. Ryumachi. 32:475–482.
  • Yao M, He L, McClements DJ, Xiao H, 2015. Uptake of gold nanoparticles by intestinal epithelial cells:impact of particle size on their absorption, accumulation and toxicity. J Agric Food Chem. 63:8044–8049.
  • Yu LE, Lanry Yung LY, Ong CN, Tan YL, Suresh Balasubramaniam K, Hartono D, Shui G, Wenk MR, Ong WY, 2007. Translocation and effects of gold nanoparticles after inhalation exposure in rats. J Nanotechnol. 1:235–242.
  • Zamir E, Read RW, Affeldt JC, Ramaswamy D, Rao NA, 2001. Gold induced interstitial keratitis. Br J Ophthalmol. 85:1386–1387.
  • Zhang J, Zhang Y, Richmond W, Wang HP. 2010. Processing technologies for gold-telluride ores. Int J Miner Metall Mater. 17:1–10.
  • Zhang Q, Hitchins VM, Schrand AM, Hussain SM, Goering PL, 2011. Uptake of gold nanoparticles in murine macrophage cells without cytotoxicity or production of pro-inflammatory mediators. Nanotoxicology. 5:284–295.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.